The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial

European Journal of Cancer

Volumn 37, Issue 1, 2001, Pages 23-31

  Steuer Vogt, M K ^a   Bonkowsky, V ^a   Ambrosch, P ^b   Scholz, M ^a   Nei, A ^a   Strutz, J ^c   Hennig, M ^a   Lenarz, T ^d   Arnold, W ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Disease free survival; Disease specific survival; Head and neck carcinoma; Herbal medicine; Mistletoe extract; Mistletoe lectin 1

Indexed keywords

LECTIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOSTIMULATION; LARGE GRANULAR LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VISCUM ALBUM;

ADULT; AGED; ALGORITHMS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MISTLETOE; NEOPLASM RECURRENCE, LOCAL; PHYTOTHERAPY; PLANTS, MEDICINAL; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035146589     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00360-9     Document Type: Article

References (40)

1. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey
2. The prevalence of complementary/alternative medicine in cancer: A systematic review
3. Prevalence of complementary/alternative medicine for children: A systematic review
4. Alternative therapies used by women with breast cancer in four ethnic populations
5. The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost
6. Use of alternative medicine in oncology patients
7. Mistletoe treatment for cancer: Review of controlled trials in humans
8. Treatment of advanced pancreatic cancer with mistletoe: Results of a pilot trial
9. Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity
10. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems
11. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients
12. Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract
13. The immunopharmacology of head and neck cancer: An update
14. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects
15. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers
16. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction
17. In vitro T-lymphocyte function in head and neck cancer patients
18. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis
19. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients
20. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract
21. A comparison of sample size methods for the logrank statistic
22. Graphical comparison of nonparametric curves
23. A multiple testing procedure for clinical trials
24. Alternative medicine - The risks of untested and unregulated remedies
25. Current options in management of head and neck cancer patients
26. Prognostic value of histologic findings in neck dissections for squamous cell carcinoma
27. Distant metastases from head and neck squamous cell carcinomas
28. Synchronous and metachronous head and neck carcinomas
29. Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours
30. The National Cancer Data Base report on cancer of the head and neck
31. Mistletoe hepatitis
32. Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract
33. Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared to the standardized extract
34. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration
35. Long-term administration of galactoside-specific mistletoe lectin in an animal model: No protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response
36. Lymphocyte subsets in tumour patients during subcutaneous mistletoe therapy
37. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients